Investigational Site Number :4400001

Vilnius LT-08406

0 studies enrolling now · 9 studies all time

What they study most

Asthma, Chronic Kidney Diseases, Heart Failure, Non-relapsing Secondary Progressive Multiple Sclerosis, Plasma Cell Myeloma, Progressive Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia, Type 2 Diabetes Mellitus

Studies at this site

• A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant — Running, not enrolling
• A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. — Running, not enrolling
• Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma — Running, not enrolling
• Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion) — Completed
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) — Completed
• Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) — Completed
• Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) — Stopped early
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk — Stopped early
• Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia — Stopped early